In Brief
This article was originally published in The Rose Sheet
Executive Summary
Skin-Care Devices Are Next $1 Bil. Market
You may also be interested in...
L’Oreal Powering Down Clarisonic After 16 Years Of Innovation, More Than 15 Million Devices Sold
The decision to close Clarisonic follows a €234m impairment charge recorded in 2016 and comes as L’Oreal faces tough strategic decisions in a global economy ravaged by the COVID-19 crisis.
FDA Warns Quasar For Lack Of Proper Skin-Care Device Clearance; Firm Cites Mix-Up
An FDA warning letter to Quasar Bio-Tech suggests the marketer of Baby Quasar and Quasar MD lacks correct 510(k) device clearance and is improperly marketing its home-use skin-care device products. Quasar maintains it holds the correct clearances, and that FDA may be confused by its product nomenclature.